Why More Can Stop Helping: Absorptive Capacity and Robustness

The PIPE curve shows a rise and fall in estimated patent additionality, but a curve alone does not explain its own shape. This chapter examines the explanation the study offers—absorptive capacity—and then tests how far the pattern travels across outcomes, samples, time horizons, and specifications. The practical judgment is deliberately two-part: the inverted-U is a meaningful empirical result within the study’s setting, while the reason for it and its applicability elsewhere require more caution.

Absorptive capacity is a bottleneck, not a label for “good firms”

Absorptive capacity describes a firm’s ability to recognize useful external knowledge, assimilate it, and exploit it in its own work. In the PIPE setting, the concept names the organizational work between receiving a grant and producing an innovation output. Public money can make resources available, but the firm still has to understand what it needs, combine new inputs with existing knowledge, coordinate the project, and carry the work through to a result.

That definition is more precise than saying that larger firms or more sophisticated firms simply benefit more. Capacity is not a permanent ranking of firms. It can depend on a project’s technical demands, the availability of skilled people, the firm’s prior experience with R&D, the organization of the work, and the external knowledge it can access. The study emphasizes that SMEs are heterogeneous in these respects. A firm may be highly capable in one product domain and still lack the organizational readiness to deploy a large, unfamiliar research program.

The concept helps separate three constraints that can be mixed together under the word “funding.” The first is financial insufficiency: the firm cannot pay for a necessary input without assistance. The second is complementary-input scarcity: money is available, but the project also requires specialized labor, equipment, or external expertise that must arrive in a workable combination. The third is deployment capacity: the firm has resources on paper but cannot coordinate or absorb them fast enough to turn them into productive research. These constraints can produce similar short-run patent outcomes while implying different policy responses.

At a low grant dose, PIPE support may not overcome the first two constraints. An award can reduce the cost of a project and still leave a critical bottleneck in place. If one missing researcher, instrument, or technical relationship is essential, partial funding may not change the project’s feasible path. In that case, low estimated additionality does not mean the grant had no financial value. It means that the observed support may have been insufficient to produce a measurable patent response within the study’s outcome definition and horizon.

As the dose rises, support can make complementary inputs usable together. A firm may be able to assemble the personnel, equipment, and external knowledge needed to proceed. That is the economic intuition behind the rising section of the curve: an additional unit of funding can unlock a combination rather than merely enlarge an already functioning budget. The study’s estimates are consistent with this threshold-like logic, but they do not measure which complement was missing in each project.

At a high dose, the binding constraint may move inside the organization. More resources can require more recruiting, supervision, technical coordination, financial administration, and decision-making. A small firm’s routines and managerial bandwidth may not expand at the same pace as its grant. Resources can be delayed, spread thinly, or directed toward benefits that do not become patents during the observed window. The resulting diminishing marginal response is therefore compatible with a grant that remains useful while the next increment produces less measured additionality.